Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Web questionnaire survey of physicians and patients on the side effects of trifluridine/tipiracil.

Scientific reports·2026
Same author

Research Survey on Recognition of Medical Oncology among Medical Students and Junior Residents in Japan.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Metabolic and functional pathways of gut microbiota in patients with gastric cancer.

Scientific reports·2026
Same author

RAS/BRAF wild-type metastatic high-methylated colorectal cancer has gene expression patterns related to MSI-H and BRAF V600E mutant: a translational research.

Scientific reports·2026

Related Experiment Video

Updated: Jul 7, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

[Predictive markers for platinum-based chemotherapy].

Takako Eguchi Nakajima1, Yasuhide Yamada

  • 1Outpatient Oncology Division, National Cancer Center Hospital, Tokyo.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|February 19, 2008
PubMed
Summary

This study evaluates predictive markers for platinum-based chemotherapy resistance, highlighting the need for clinical validation of "-omic approach" markers in randomized trials.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Biomarker Discovery

Context:

  • Platinum-based chemotherapy is a cornerstone in cancer treatment, but variable patient responses necessitate predictive markers.
  • Existing predictive markers lack validation from randomized studies, limiting clinical utility.
  • Understanding chemoresistance mechanisms is crucial for developing effective predictive tools.

Purpose:

  • To evaluate candidate predictive markers for platinum-based chemotherapy based on chemoresistance mechanisms.
  • To assess the transition from candidate/pathway approaches to comprehensive "-omic" strategies for marker detection.
  • To emphasize the necessity of rigorous clinical validation for predictive markers.

Summary:

  • Investigated markers like Na(+), K(+)-ATPase, MRP1, GST-pi, MT, ERCC1/2, and p53 in relation to platinum drug resistance.

More Related Videos

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Related Experiment Videos

Last Updated: Jul 7, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

  • Noted advancements in detection methods, enabling a shift towards broader "-omic" approaches.
  • Highlighted the importance of standardized measurement and evaluation in prospective randomized controlled studies.

    • Impact:

    • Aims to facilitate more efficient and economical cancer diagnoses through validated predictive markers.
    • Stresses the need for future clinical validation in large-scale, prospective randomized trials.
    • Potential to optimize platinum-based chemotherapy selection and improve patient outcomes.